5-海因乙酸 | 5427-26-9

• 物质功能分类: 化学试剂 - 有机试剂 - 脂肪酸
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 5-海因乙酸
• 中文别名: 乙内酰脲-5-乙酸
• 英文名称: 5-hydantoinacetic acid
• 英文别名: hydantoin 5-acetic acid；2-(2,5-dioxoimidazolidin-4-yl)acetic acid
• CAS: 5427-26-9
• 化学式: C₅H₆N₂O₄
• mdl: MFCD00005267
• 分子量: 158.114
• InChiKey: DQQLZADYSWBCOX-UHFFFAOYSA-N

物化性质

• 熔点：
  214-215 °C (dec.)(lit.)
• 沸点：
  283.16°C (rough estimate)
• 密度：
  1.5902 (rough estimate)
• 稳定性/保质期：
  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  95.5
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933990090
• 储存条件：
  常温、避光、存放在阴凉干燥处并密封保存。

SDS

Name:	5-Hydantoin Acetic Acid Material Safety Data Sheet
Synonym:	None
CAS:	5427-26-9

Section 1 - Chemical Product MSDS Name:5-Hydantoin Acetic Acid Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5427-26-9	5-Hydantoin Acetic Acid	ca 100	226-574-4

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5427-26-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Decomposes
Freezing/Melting Point: 214.00 - 215.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: 215 deg C
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H6N2O4
Molecular Weight: 158.11

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5427-26-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Hydantoin Acetic Acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 5427-26-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5427-26-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5427-26-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-海因乙酸 在 manganese(IV) oxide 、 copper(II) sulfate 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 29.0h， 以10.97%的产率得到乳清酸
  参考文献：
  名称：

  嘧啶核碱基生物合成的非酶类似物

  摘要：

  生命起源的代谢理论认为，无机催化剂使自组织化学前体能够进入代谢途径，包括那些制造遗传分子的化学前体。最近，显示许多核心代谢途径的非酶版本的实验已经开始支持这一想法。然而，沿从头核糖核苷酸生物合成途径的非酶反应序列的实验演示是有限的。在这里，我们展示了将天冬氨酸转化为乳清酸的嘧啶核碱基生物合成的所有三个反应在 60 ℃ 下进行，无需光化学，在金属（例如 Cu 2+ 和 Mn 4+ ）存在的情况下，在水性条件下进行。将反应组合成一锅变体也是可能的。生命可能并没有从头开始发明嘧啶核碱基生物合成，而只是简单地改进了现有的非酶反应通道。这项工作是将生命起源的代谢理论与以遗传分子为中心的代谢理论结合起来的第一步。

  DOI：

  10.1002/anie.202117211
• 作为产物：
  描述：

  [(2,5-dioxo-imidazolidin-4-yl)-acetyl]-urea 在 氢氧化钾 作用下， 生成 5-海因乙酸
  参考文献：
  名称：

  Jerzmanowska-Sienkiewiczowa, Roczniki Chemii, 1935, vol. 15, p. 204

  摘要：

  DOI：

文献信息

• Synthetic chemical diversity: solid phase synthesis of libraries of C2 symmetric inhibitors of HIV protease containing diamino diol and diamino alcohol cores
  作者：Gary T. Wang、Sam Li、Norman Wideburg、Grant A. Krafft、Dale J. Kempf

  DOI：10.1021/jm00016a001

  日期：1995.8

  structure--activity relationship (SAR) studies. To expand the scope of solid phase synthesis beyond the capability of the traditional method of solid phase synthesis for peptides, a strategy was developed for bi-directional solid phase synthesis starting with diamino alcohol or diamino diol core structures. The strategy relies on using bifunctional linkers to modify the core structures, simultaneously protecting

  为了高效率地产生用于药物筛选的大量结构多样的化合物，一直在追求非低聚有机化合物的固相合成。这些化合物被称为化学多样性文库或组合文库（当以组合方式进行合成时），可用于从头发现药物前导或方便的结构-活性关系（SAR）研究。为了将固相合成的范围扩展到传统的肽固相合成方法的能力之外，开发了一种从二氨基醇或二氨基二醇核心结构开始的双向固相合成策略。该策略依靠使用双功能链接程序来修改核心结构，同时保护核的羟基或二醇部分，并提供羧基以将修饰的核连接到固体载体上。然后将与固相支持物相连的修饰核的两个NH2基团脱保护，并与多种胺反应试剂（羧酸，磺酰氯，异氰酸酯，氯甲酸酯等）反应，以在两个方向上扩展分子。此策略已成功应用于包含已知的基于对称性的二氨基二醇和二氨基醇核心结构的HIV蛋白酶C2对称抑制剂文库的自动平行合成，因此可以方便地访问此系列中的大量类似物。使用此方法合成了300多种离散化合物的文库，以鉴定有效的（IC50
• DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES
  申请人：Kasai Shizuo

  公开号：US20120071489A1

  公开（公告）日：2012-03-22

  The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, which has a superior RBP4-lowering action and is useful as a pharmaceutical composition for the prophylaxis or treatment of a disease or condition mediated by an increase in RBP4.

  本发明涉及一种化合物，其化学式如下所示，其中每个符号如本说明书中所定义，该化合物具有优越的降低RBP4作用，并且可用作预防或治疗由RBP4增加介导的疾病或病况的药物组合物。
• [EN] INHIBITORS OF APOL1 AND USE OF THE SAME<br/>[FR] INHIBITEURS D'APOL1 ET LEUR UTILISATION
  申请人：VERTEX PHARMA

  公开号：WO2021252859A1

  公开（公告）日：2021-12-16

  The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

  本公开提供了至少一种化合物、重氢化衍生物或药用可接受的盐，选自公式(I)化合物、其重氢化衍生物以及任何前述物质的药用可接受的盐，包含同一的组成物，以及制造和使用同一的方法，包括用于治疗APOL1介导的肾脏疾病。
• Selective Inhibition of an Apicoplastic Aminoacyl-tRNA Synthetase from<i>Plasmodium falciparum</i>
  作者：Rob Hoen、Eva Maria Novoa、Alba López、Noelia Camacho、Laia Cubells、Pedro Vieira、Manuel Santos、Patricia Marin-Garcia、Jose Maria Bautista、Alfred Cortés、Lluís Ribas de Pouplana、Miriam Royo

  DOI：10.1002/cbic.201200620

  日期：2013.3.4

  antimalarials: We have designed, synthesized, and tested a battery of lysyl‐tRNA synthetase inhibitors based on the structure of lysyl‐adenylate, the natural substrate intermediate of the tRNA lysinylation reaction. We show that some of these compounds selectively inhibit Plasmodium apicoplastic lysyl‐tRNA synthetase without inhibiting its human orthologue.

  合理设计抗疟疾药物：我们基于赖氨酰腺苷酸（tRNA赖氨酰化反应的天然底物中间体）的结构设计，合成和测试了一系列赖氨酰tRNA合成酶抑制剂。我们显示出其中一些化合物选择性抑制疟原虫脂生性赖氨酰-tRNA合成酶而不抑制其人类直系同源物。
• [EN] SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION<br/>[FR] PETITES MOLÉCULES DIRIGÉES CONTRE LE CÉRÉBLON POUR AMÉLIORER LA FONCTION DES LYMPHOCYTES T EFFECTEURS
  申请人：H LEE MOFFITT CANCER CENTER & RES INST INC

  公开号：WO2017161119A1

  公开（公告）日：2017-09-21

  Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.

  披露了针对小脑蛋白以增强效应T细胞功能的小分子。还披露了制造这些分子的方法以及使用它们治疗各种疾病状态的方法。

表征谱图